General


Tissue “Agnostic” Genomic Based Treatment With Vitrakvi and Keytruda – A Paradigm Shift in Cancer Treatment (11-28-2018)

The US Food and Drug Administration (FDA) on Monday approved a new precision cancer medicine Vitrakvi (larotrectinib) for the treatment of adult and pediatric solid tumors that have a targetable biomarker known as a neurotrophic receptor tyrosine kinase... Continue Reading

Patients with rare, incurable digestive tract cancers respond to new drug combination (11-19-2018)

Dublin, Ireland: Patients with rare, but incurable cancers of the digestive tract have responded well to a combination of two drugs that block the MEK and BRAF pathways, which drive the disease in some cases. They have survived for longer without the... Continue Reading

New Treatment Approved for Influenza (10-26-2018)

The Food and Drug Administration (FDA) has approved Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in patients aged ≥12 years old who have been symptomatic for no more than 48 hours. Xofluza is a first-in-class, single-dose... Continue Reading

AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström’s Macroglobulinemia, a Rare Type of Blood Cancer (09-4-2018)

PRESS RELEASE PR Newswire Aug. 27, 2018, 07:00 AM NORTH CHICAGO, Ill., Aug. 27, 2018 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) approved... Continue Reading

FDA Approves Iobenguane I 131 (Azedra) for Rare Neuroendocrine Tumors (08-2-2018)

The US Food and Drug Administration (FDA) today approved Azedra (iobenguane I 131) for the treatment of pheochromocytoma or paraganglioma, which are rare neuroendocrine tumors of the adrenal gland and other tissue areas. About Pheochromocytoma and Paraganglioma Pheochromocytomas... Continue Reading

FDA Approves First non-opioid Treatment for Management of Opioid Withdrawal Symptoms in Adults (05-24-2018)

Encouraging more widespread innovation and development of safe and effective treatments for opioid use disorder remains top agency priority The U.S. Food and Drug Administration today approved Lucemyra (lofexidine hydrochloride) for the mitigation of... Continue Reading

FDA Approves Aimovig, A Novel Preventive Treatment for Migraine Headaches (05-21-2018)

According to Dr. Jessica Ailani, MD, associate professor of neurology at MedStar’s Georgetown University Hospital and director of the MedStar Georgetown Headache Center, migraines affect over 36 million people in the U.S. yet they are still a poorly... Continue Reading

What is a Venous Access Device and What Types are Used for Cancer Patients? (05-9-2018)

A venous access device (VAD) is a surgically implanted device that provides long-term access to a major vein. A VAD can be useful for patients undergoing systemic treatment with precision cancer medicines or chemotherapy because it allows for a single... Continue Reading

Lutathera Pepetide Receptor Radionuclide Therapy for NETs (05-3-2018)

CancerConnect News: Lutathera (lutetium Lu 177 dotatate) was recently approved for the treatment of neuroendocrine tumors (NETs) that typically occur in the pancreas and gastrointestinal tract. This is the first time a radioactive drug, or radiopharmaceutical,... Continue Reading

CancerConnect – Online Support & Networking for Cancer Patients (03-21-2018)

Social networking sites are rapidly growing, giving patients with cancer a place to connect with others. On line social groups on Facebook, discussion boards, and peer to peer networking connections have become widely available and serve some specific... Continue Reading

Next Page »